头孢哌酮/舒巴坦联合米诺环素治疗泛耐药鲍氏不动杆菌血流感染临床观察

Clinical observation of efficacy of cefoperazone/sulbactam combined with minocycline in treatment of bloodstream infections caused by pandrug-resistant Acinetobacter baumannii

目的探讨头孢哌酮/舒巴坦联合米诺环素治疗泛耐药鲍氏不动杆菌(PDRAB)血流感染的临床疗效,为指导临床合理用药提供参考。方法收集医院2008年12月-2011年12月使用头孢哌酮/舒巴坦联合米诺环素治疗PDRAB所致血流感染患者临床资料,对其药敏、临床疗效和预后进行回顾性分析。结果 25例血流感染患者使用头孢哌酮/舒巴坦联合米诺环素治疗后临床总有效率80.0%,细菌清除率64.0%,死亡4例,病死率16.0%;生存组患者肾功能逐渐好转,降钙素原下降,而死亡组肾功能、降钙素原升高。结论 PDRAB引起的血流感染,使用头孢哌酮/舒巴坦联合米诺环素具有较好疗效。

OBJECTIVE To observe the efficacy of cefoperazone/ sulbactam combined with minocycline in treatment of bloodstream infections caused by pandrug-resistant Acinetobacter baumannii （MDRAB） so as to guide the reasonable clinical use of antibiotics. METHODS The patients with bloodstream infections caused by PDRAB, who were treated with cefoperazone/sulbactam combined with minocycline from Dec 2008 to Dec 2011, were enrolled in the study, then the clinical data of the subjects were collected, and the drug susceptibility, clinical efficacy, and prognosis were retrospectively analyzed. RESULTS After the treatment of 25 cases of bloodstream infections patients with cefoperazone/sulbactam plus minocycline, the total clinical effective rate was 80. 0%, the bacterial eradication rate was 64.0%, and 4 cases died with the mortality of 16.0%. The renal function was improved,and the procalcitonin was decreased in the survival group, while the renal function was not improved in the death group, with the procalcitonin elevated. CONCLUSION The cefoperazone/sulbactam combined with minocycline can achieve good clinical efficacy in treatment of the bloodstream infections caused by PDRAB.